Lastly, although epigenetic silencing of PTEN in prostate cancer is uncommon, demethylating agents able to restore PTEN expression may also offer a beneficial therapeutic approach for patients with PTEN silencing [129]. This evidence concerns the gene PTEN and Familial prostate cancer.